VYNE vs. NLTX, PROC, NMRA, LXEO, TIL, SNTI, RAPT, TNXP, CCCC, and ZNTL
Should you be buying VYNE Therapeutics stock or one of its competitors? The main competitors of VYNE Therapeutics include Neoleukin Therapeutics (NLTX), Procaps Group (PROC), Neumora Therapeutics (NMRA), Lexeo Therapeutics (LXEO), Instil Bio (TIL), Senti Biosciences (SNTI), RAPT Therapeutics (RAPT), Tonix Pharmaceuticals (TNXP), C4 Therapeutics (CCCC), and Zentalis Pharmaceuticals (ZNTL). These companies are all part of the "pharmaceutical products" industry.
VYNE Therapeutics vs.
Neoleukin Therapeutics (NASDAQ:NLTX) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.
VYNE Therapeutics has a consensus target price of $6.25, indicating a potential upside of 337.06%. Given VYNE Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe VYNE Therapeutics is more favorable than Neoleukin Therapeutics.
Neoleukin Therapeutics has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -6,896.55%. Neoleukin Therapeutics' return on equity of -37.22% beat VYNE Therapeutics' return on equity.
Neoleukin Therapeutics received 14 more outperform votes than VYNE Therapeutics when rated by MarketBeat users. However, 67.92% of users gave VYNE Therapeutics an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote.
52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Comparatively, 4.8% of VYNE Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
VYNE Therapeutics has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, VYNE Therapeutics had 6 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 6 mentions for VYNE Therapeutics and 0 mentions for Neoleukin Therapeutics. Neoleukin Therapeutics' average media sentiment score of 0.00 equaled VYNE Therapeutics'average media sentiment score.
Neoleukin Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500.
Summary
VYNE Therapeutics beats Neoleukin Therapeutics on 12 of the 16 factors compared between the two stocks.
Get VYNE Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VYNE Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VYNE) was last updated on 4/25/2025 by MarketBeat.com Staff
